GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (STU:AB3A) » Definitions » Cyclically Adjusted Book per Share

Sarepta Therapeutics (STU:AB3A) Cyclically Adjusted Book per Share : €9.56 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sarepta Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Sarepta Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was €9.359. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €9.56 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Sarepta Therapeutics's average Cyclically Adjusted Book Growth Rate was 5.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 11.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 16.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Sarepta Therapeutics was 27.80% per year. The lowest was -15.20% per year. And the median was -4.00% per year.

As of today (2024-06-01), Sarepta Therapeutics's current stock price is €116.55. Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €9.56. Sarepta Therapeutics's Cyclically Adjusted PB Ratio of today is 12.19.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sarepta Therapeutics was 38.73. The lowest was 3.66. And the median was 11.57.


Sarepta Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Cyclically Adjusted Book per Share Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.51 6.03 7.56 8.76 9.21

Sarepta Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.04 9.02 9.73 9.21 9.56

Competitive Comparison of Sarepta Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sarepta Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9.359/131.7762*131.7762
=9.359

Current CPI (Mar. 2024) = 131.7762.

Sarepta Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 5.410 100.560 7.089
201409 5.377 100.428 7.055
201412 4.862 99.070 6.467
201503 4.486 99.621 5.934
201506 3.549 100.684 4.645
201509 2.617 100.392 3.435
201512 3.830 99.792 5.058
201603 2.727 100.470 3.577
201606 2.258 101.688 2.926
201609 6.699 101.861 8.666
201612 5.829 101.863 7.541
201703 7.303 102.862 9.356
201706 6.075 103.349 7.746
201709 9.059 104.136 11.464
201712 10.293 104.011 13.041
201803 9.619 105.290 12.039
201806 9.019 106.317 11.179
201809 8.222 106.507 10.173
201812 12.767 105.998 15.872
201903 16.099 107.251 19.780
201906 13.087 108.070 15.958
201909 12.129 108.329 14.754
201912 9.794 108.420 11.904
202003 13.290 108.902 16.082
202006 11.807 108.767 14.305
202009 9.612 109.815 11.534
202012 7.889 109.897 9.460
202103 5.640 111.754 6.650
202106 5.044 114.631 5.798
202109 4.991 115.734 5.683
202112 9.426 117.630 10.560
202203 8.892 121.301 9.660
202206 7.851 125.017 8.275
202209 4.958 125.227 5.217
202212 4.132 125.222 4.348
202303 7.147 127.348 7.396
202306 7.337 128.729 7.511
202309 7.657 129.860 7.770
202312 8.407 129.419 8.560
202403 9.359 131.776 9.359

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Sarepta Therapeutics  (STU:AB3A) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sarepta Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=116.55/9.56
=12.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sarepta Therapeutics was 38.73. The lowest was 3.66. And the median was 11.57.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Sarepta Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (STU:AB3A) Business Description

Industry
Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (STU:AB3A) Headlines

No Headlines